"Our team is highly skilled and experienced in treating children with all forms of cancer and blood disorders, from the most common to those rarely seen outside of the top pediatric centers."

During the past decade, AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 11 clinical trials were completed, i.e. on average, 137.5% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus" #1 sponsor was "Children's Oncology Group" with 27 trials, followed by "New Approaches to Neuroblastoma Therapy Consortium" with 9 trials sponsored, "Children's Hospital Los Angeles" with 4 trials sponsored, "GlycoMimetics Incorporated" with 2 trials sponsored and "American College of Radiology Imaging Network" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus" #1 collaborator was "National Cancer Institute (NCI)" with 41 trials as a collaborator, "Children's Oncology Group" with 3 trials as a collaborator, "SWOG Cancer Research Network" with 2 trials as a collaborator, "United Therapeutics" with 2 trials as a collaborator and "Cancer and Leukemia Group B" with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus" are "Neuroblastoma" (21 trials), "Leukemia" (13 trials), "Sarcoma" (8 trials), "Brain Tumors" (3 trials) and "Central Nervous System Tumors" (3 trials). Many other conditions were trialed in "AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus" in a lesser frequency.

Most popular intervention types in "AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus" are "Drug" (43 trials), "Biological" (18 trials), "Radiation" (17 trials), "Procedure" (14 trials) and "Other" (9 trials). Other intervention types were less common.

The name of intervention was led by "cyclophosphamide" (14 trials), "vincristine sulfate" (13 trials), "etoposide" (12 trials), "radiation therapy" (12 trials) and "filgrastim" (11 trials). Other intervention names were less common.

The vast majority of trials in "AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus" are 51 trials for "All" genders.

Currently, there are NaN active trials in "AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus". undefined are not yet recruiting, 2 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 40 completed trials in AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, 19 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".